Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

  • 📰 AP
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 51%

United States News News

United States United States Latest News,United States United States Headlines

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions reach the U.S. market in July.

HELENA, Mont. — Montana’s Republican governor indicated Monday he would sign a bill to ban gender-affirming medical care for transgender minors, but he suggested changes to make it clear that public funds could not be used to pay for surgery or hormone treatments for youth diagnosed with gender

A biosimilar is a lower-cost version of a biologic that is approved by the Food and Drug Administration after regulators determine that it is highly similar to the original product. It’s not the same as a generic drug, which is a copy of a chemical-based medicine that is easier — and cheaper — to make.

Pharmacy benefits managers, or PBMs, manage prescription drug coverage for insurers, employees and other big clients.Generally, yes, but how that affects a patient will depend on the drug and the coverage. Amgen said in January that it will offer its biosimilar, Amjevita, at prices 5% and 55% below Humira’s list price.This will vary, depending on the PBM and the employer or insurer that designs the coverage.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 728. in US

United States United States Latest News, United States United States Headlines